<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02255227</url>
  </required_header>
  <id_info>
    <org_study_id>1308162</org_study_id>
    <secondary_id>2013-004609-19</secondary_id>
    <nct_id>NCT02255227</nct_id>
  </id_info>
  <brief_title>Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD</brief_title>
  <acronym>PneumoMICI</acronym>
  <official_title>Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, randomized, open study comparing two anti-pneumococcal
      vaccination strategies in patients with Chronic Inflammatory Bowel Disease (CIBD) treated by
      immunosuppressants and/or biotherapies. At present such patients are poorly protected by
      anti-pneumococcal vaccination. In addition, vaccination efficacy in this type of patient is
      much weaker than in the general population. There are two types of anti-pneumococcal
      vaccines: firstly a polysaccharide, Pneumo23® (PSV-23®) vaccine and secondly a conjugate,
      Prevenar13® vaccine. New recommendations have just been issued by the HSCP advising
      immunocompromised patients to follow a vaccination plan combining one dose of Prevenar13®
      followed by one dose of PSV-23® after an interval of two months. In the case of young
      children infected with HIV, the recommendation is to multiply doses of Prevenar13® before the
      PSV-23® injection to improve vaccine efficacy in these immunocompromised patients.

      Our study aims to identify an optimal vaccination strategy for immunocompromised CIBD
      patients by combining use of a conjugate vaccine, Prevenar13® and a polysaccharide vaccine,
      PSV-23®. We will compare the use of one or two doses (M0 +/- M2) of Prevenar13® combined with
      a later PSV-23® injection (M4) on vaccination immunogenicity measured by antibody titer
      against at least nine of the thirteen pneumococcal serotypes contained in Prevenar13®. We
      also want to evaluate the immunological impact of these different strategies in their
      capacity to stimulate a memory B anti-pneumococcal response more effectively. With this aim,
      we are studying all immunological functional aspects of the antibodies and B lymphocytes
      induced by the two vaccine strategies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with anti-pneumococcal immunogenicity</measure>
    <time_frame>month 5</time_frame>
    <description>Measured the serologies against serotypes to Prevenar 13. Serotype to be measured are 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A 19 F and 23F using the ELISA method</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with local and/or general reaction</measure>
    <time_frame>Months 1, 3 and 5</time_frame>
    <description>self monitoring diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with inflammatory disease activity</measure>
    <time_frame>Months 1, 3, 4, 5, 12, 18, 36</time_frame>
    <description>by clinic score HBI or CDAI or Mayo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors implicated in anti-pneumococcal vaccination efficacy</measure>
    <time_frame>Month 0</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with serotype coverage of PSV-23</measure>
    <time_frame>Months 5, 12, 18 and 36</time_frame>
    <description>Measured the serologies against serotypes to Pneumo 23. Serotype to be measured are serotypes 10 and 15 using the ELISA method</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Infections, Pneumococcal</condition>
  <condition>Bowel Diseases, Inflammatory</condition>
  <arm_group>
    <arm_group_label>1 dose Prevenar13 and 1 dose PSV23</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one dose of the polysaccharide vaccine, Prevenar 13 at M0 and one dose of polysaccharide vaccine, Pneumo 23 at M4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 doses Prevenar13 and 1 dose PSV23</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one dose of the polysaccharide vaccine, Prevenar 13 at M0, one dose of the polysaccharide vaccine, Prevenar 13, at M2 and one dose of polysaccharide vaccine, Pneumo 23 at M4</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar 13</intervention_name>
    <description>one dose for arm 1 and 2 doses for arm 2</description>
    <arm_group_label>1 dose Prevenar13 and 1 dose PSV23</arm_group_label>
    <arm_group_label>2 doses Prevenar13 and 1 dose PSV23</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumo 23</intervention_name>
    <description>one dose</description>
    <arm_group_label>1 dose Prevenar13 and 1 dose PSV23</arm_group_label>
    <arm_group_label>2 doses Prevenar13 and 1 dose PSV23</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who have given their written consent in a free and informed consent

          -  Patient followed for inflammatory bowel disease (Crohn's disease, ulcerative colitis
             or indeterminate colitis), and treated for at least 3 months by immunosuppressive
             therapy and /or biotherapies and in clinical remission for at least 3 months

          -  Patient agreeing to participate in the study throughout its duration and accepting the
             procedures related to the study

          -  Contraception that the investigator judges effective for the first 12 months of the
             trial, with a negative pregnancy test

          -  Women not planning to become pregnant in the 12 months following inclusion (M0)

          -  Patient with social coverage

        Exclusion Criteria:

          -  Patients vaccinated against pneumo23 for less than 5 years

          -  Other vaccination during the month before inclusion

          -  Patient develops a febrile illness (at least 37 ° C 5 measured orally) or acute
             infection in the week before vaccination

          -  The patient has a flare up of IBD the day of vaccination (Harvey-Brasdshaw score of at
             least 6 or CDAI &gt; 220 for Crohn's disease or Mayo Clinic score of at least 4 for UC
             and indeterminate colitis)

          -  Patients with an ongoing pregnancy the day of vaccination

          -  Patient with a known history of neuropathy as Guillain-Barré syndrome.

          -  Patients with known infection with HIV and / or HBV (HBsAg positive) and / or HCV

          -  Patient with other severe immune deficiency

          -  Patients who received immunoglobulin infusions of blood products, or of monoclonal
             antibodies (except anti-TNF) in the 3 months prior to vaccination

          -  Patient institutionalized, or deprived of liberty administrative or judicial

          -  Patients treated without immunosuppressive therapy or biotherapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Roblin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier ROBLIN, MD</last_name>
    <phone>(0)477828985</phone>
    <phone_ext>+33</phone_ext>
    <email>xavier.roblin@chu-st-etienne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathurin FUMERY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mathurin FUMERY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucine Vuitton, PU PH</last_name>
    </contact>
    <investigator>
      <last_name>Lucine Vuitton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane Koch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romain Alwegg, MD</last_name>
    </contact>
    <investigator>
      <last_name>Romain Alwegg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florent Gonzalez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ludovic Caillo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Danan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet II</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Hebuterne, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xavier Hebuterne, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérome Filippi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia Arab, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane Nancey, PU PH</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane NANCEY, PU PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard FLOURIE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles Boschetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karine Stroeymeyt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion CHAUVENET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume Savoye, PU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume Savoye, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Armengol-Debeir, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier ROBLIN</last_name>
    </contact>
    <investigator>
      <last_name>Frederic Lucht, PU PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Roblin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claire Guglielminotti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christiane Defontaine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisabeth Bothelo-Nevers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale Fouilloux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2014</study_first_submitted>
  <study_first_submitted_qc>October 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccination</keyword>
  <keyword>randomized</keyword>
  <keyword>anti-pneumococcal</keyword>
  <keyword>Pneumo 23</keyword>
  <keyword>Prevenar 13</keyword>
  <keyword>Chronic Inflammatory Bowel Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

